{"docId":"AFP_ENG_20090724.0254","headline":"India's Ranbaxy's Q2 profit soars but sees year loss","named_entity":{"FDA":[[8,"ORGANIZATION",8,8],[11,"ORGANIZATION",2,2],[12,"ORGANIZATION",7,7],[13,"ORGANIZATION",16,16]],"United States":[[3,"LOCATION",18,19]],"Daiichi Sankyo":[[2,"ORGANIZATION",14,15],[13,"ORGANIZATION",1,2],[14,"ORGANIZATION",1,2]],"Ranbaxy Laboratories":[[2,"ORGANIZATION",6,7]],"US Food and Drug Administration":[[8,"ORGANIZATION",2,6]],"US":[[9,"LOCATION",24,24]],"USA":[[8,"LOCATION",17,17]],"Japan":[[2,"LOCATION",12,12]],"New Delhi-based":[[5,"MISC",5,6]],"Japanese":[[15,"MISC",3,3]],"India":[[1,"LOCATION",1,1],[14,"LOCATION",13,13]],"Atul Sobti":[[10,"PERSON",27,28]],"Tokyo-based":[[13,"MISC",6,6]],"Indian":[[2,"MISC",2,2],[6,"MISC",11,11],[11,"MISC",32,32]],"Ranbaxy":[[1,"ORGANIZATION",3,3],[3,"ORGANIZATION",2,2],[4,"ORGANIZATION",1,1],[7,"ORGANIZATION",8,8],[8,"ORGANIZATION",20,20],[10,"ORGANIZATION",22,22],[11,"ORGANIZATION",14,14],[12,"ORGANIZATION",9,9],[13,"ORGANIZATION",4,4],[13,"ORGANIZATION",25,25],[15,"ORGANIZATION",13,13]]},"cluster_json":[[{"sent_ind":3,"word":"its","mention_type":"PRONOMINAL","token_ind":13,"end_ind":14},{"sent_ind":10,"word":"Ranbaxy 's","mention_type":"PROPER","token_ind":22,"end_ind":24},{"sent_ind":13,"word":"Ranbaxy 's","mention_type":"PROPER","token_ind":4,"end_ind":6},{"sent_ind":12,"word":"it","mention_type":"PRONOMINAL","token_ind":23,"end_ind":24},{"sent_ind":4,"word":"Ranbaxy 's","mention_type":"PROPER","token_ind":1,"end_ind":3},{"sent_ind":2,"word":"Ranbaxy Laboratories","mention_type":"PROPER","token_ind":6,"end_ind":8},{"sent_ind":3,"word":"its","mention_type":"PRONOMINAL","token_ind":22,"end_ind":23},{"sent_ind":15,"word":"Ranbaxy","mention_type":"PROPER","token_ind":13,"end_ind":14},{"sent_ind":1,"word":"Ranbaxy 's","mention_type":"PROPER","token_ind":3,"end_ind":5},{"sent_ind":3,"word":"Ranbaxy","mention_type":"PROPER","token_ind":2,"end_ind":3},{"sent_ind":3,"word":"Ranbaxy , which has been buffeted by major regulatory problems in its largest market , the United States","mention_type":"PROPER","token_ind":2,"end_ind":20},{"sent_ind":12,"word":"Ranbaxy","mention_type":"PROPER","token_ind":9,"end_ind":10},{"sent_ind":13,"word":"Ranbaxy","mention_type":"PROPER","token_ind":25,"end_ind":26},{"sent_ind":8,"word":"Ranbaxy","mention_type":"PROPER","token_ind":20,"end_ind":21},{"sent_ind":7,"word":"Ranbaxy","mention_type":"PROPER","token_ind":8,"end_ind":9}],[{"sent_ind":1,"word":"India 's Ranbaxy 's Q2 profit","mention_type":"PROPER","token_ind":1,"end_ind":7},{"sent_ind":14,"word":"India 's","mention_type":"PROPER","token_ind":13,"end_ind":15}],[{"sent_ind":14,"word":"Daiichi Sankyo","mention_type":"PROPER","token_ind":1,"end_ind":3},{"sent_ind":2,"word":"Daiichi Sankyo","mention_type":"PROPER","token_ind":14,"end_ind":16},{"sent_ind":14,"word":"its","mention_type":"PRONOMINAL","token_ind":4,"end_ind":5},{"sent_ind":13,"word":"it","mention_type":"PRONOMINAL","token_ind":23,"end_ind":24},{"sent_ind":13,"word":"it","mention_type":"PRONOMINAL","token_ind":12,"end_ind":13},{"sent_ind":13,"word":"Daiichi Sankyo","mention_type":"PROPER","token_ind":1,"end_ind":3},{"sent_ind":13,"word":"Daiichi Sankyo , Ranbaxy 's Tokyo-based pharmaceutical parent","mention_type":"PROPER","token_ind":1,"end_ind":9}],[{"sent_ind":2,"word":"foreign exchange gains","mention_type":"NOMINAL","token_ind":29,"end_ind":32},{"sent_ind":6,"word":"Foreign exchange gains","mention_type":"NOMINAL","token_ind":1,"end_ind":4}],[{"sent_ind":9,"word":"US","mention_type":"PROPER","token_ind":24,"end_ind":25},{"sent_ind":3,"word":"its largest market , the United States","mention_type":"NOMINAL","token_ind":13,"end_ind":20},{"sent_ind":3,"word":"major regulatory problems in its largest market , the United States","mention_type":"NOMINAL","token_ind":9,"end_ind":20}],[{"sent_ind":4,"word":"a year earlier","mention_type":"NOMINAL","token_ind":29,"end_ind":32},{"sent_ind":9,"word":"a year earlier","mention_type":"NOMINAL","token_ind":15,"end_ind":18},{"sent_ind":7,"word":"the year","mention_type":"NOMINAL","token_ind":37,"end_ind":39}],[{"sent_ind":5,"word":"Analysts","mention_type":"NOMINAL","token_ind":1,"end_ind":2},{"sent_ind":4,"word":"sharply surprising analysts","mention_type":"NOMINAL","token_ind":33,"end_ind":36}],[{"sent_ind":5,"word":"the New Delhi-based company","mention_type":"NOMINAL","token_ind":4,"end_ind":8},{"sent_ind":7,"word":"the company","mention_type":"NOMINAL","token_ind":20,"end_ind":22},{"sent_ind":7,"word":"it","mention_type":"PRONOMINAL","token_ind":23,"end_ind":24}],[{"sent_ind":6,"word":"the Indian rupee","mention_type":"NOMINAL","token_ind":10,"end_ind":13}],[{"sent_ind":8,"word":"FDA","mention_type":"PROPER","token_ind":8,"end_ind":9},{"sent_ind":12,"word":"the FDA","mention_type":"PROPER","token_ind":6,"end_ind":8},{"sent_ind":11,"word":"The FDA","mention_type":"PROPER","token_ind":1,"end_ind":3},{"sent_ind":13,"word":"FDA","mention_type":"PROPER","token_ind":16,"end_ind":17}],[{"sent_ind":10,"word":"Atul Sobti","mention_type":"PROPER","token_ind":27,"end_ind":29}],[{"sent_ind":11,"word":"their","mention_type":"PRONOMINAL","token_ind":24,"end_ind":25},{"sent_ind":10,"word":"us","mention_type":"PRONOMINAL","token_ind":15,"end_ind":16},{"sent_ind":10,"word":"Our","mention_type":"PRONOMINAL","token_ind":2,"end_ind":3}],[{"sent_ind":10,"word":"Ranbaxy 's new chief executive","mention_type":"NOMINAL","token_ind":22,"end_ind":27}],[{"sent_ind":15,"word":"the Japanese firm","mention_type":"NOMINAL","token_ind":2,"end_ind":5},{"sent_ind":15,"word":"its","mention_type":"PRONOMINAL","token_ind":10,"end_ind":11}],[{"sent_ind":15,"word":"it","mention_type":"PRONOMINAL","token_ind":17,"end_ind":18},{"sent_ind":15,"word":"the value of its investment in Ranbaxy","mention_type":"NOMINAL","token_ind":7,"end_ind":14}],[],[],[],[]],"text":[["India","'s","Ranbaxy","'s","Q2","profit","soars","but","sees","year","loss","."],["Top","Indian","generic","drugs","firm","Ranbaxy","Laboratories",",","a","unit","of","Japan","'s","Daiichi","Sankyo",",","reported","Friday","net","profit","soared","during","the","second","quarter",",","swelled","by","foreign","exchange","gains","."],["But","Ranbaxy",",","which","has","been","buffeted","by","major","regulatory","problems","in","its","largest","market",",","the","United","States",",","maintained","its","forecast","of","a","loss","for","full","year","2009","."],["Ranbaxy","'s","net","profit","for","the","three","months","to","June","jumped","to","6.93","billion","rupees","-LRB-","139","million","dollars","-RRB-","from","229","million","rupees","in","the","same","period","a","year","earlier",",","sharply","surprising","analysts","."],["Analysts","had","expected","the","New","Delhi-based","company","to","snap","three","straight","quarters","of","losses","with","a","net","profit","of","around","3.7","billion","rupees","."],["Foreign","exchange","gains",",","thanks","to","a","rise","in","the","Indian","rupee",",","totalled","8.06","billion","rupees","."],["But","stripping","out","the","currency","gains",",","Ranbaxy","posted","a","second-quarter","profit","after","tax","of","633","millon","rupees","and","the","company","said","it","was","sticking","to","an","earlier","forecast","net","loss","of","eight","billion","rupees","for","the","year","."],["``","US","Food","and","Drug","Administration","-LRB-","FDA","-RRB-","actions","adversely","impacted","business","performance","in","the","USA",",","''","Ranbaxy","said","in","a","statement","."],["Sales","fell","to","17.95","billion","rupees","during","the","second-quarter","period","from","18.29","billion","rupees","a","year","earlier",",","hit","by","a","fall","in","US","sales","."],["``","Our","balanced","market","mix","with","a","clear","focus","on","emerging","markets","has","helped","us","mitigate","these","pressures",",","''","said","Ranbaxy","'s","new","chief","executive","Atul","Sobti",",","who","took","over","the","job","two","months","ago","."],["The","FDA","last","September","banned","imports","of","over","30","generic","drugs","produced","by","Ranbaxy","including","antibiotics","and","AIDS","drugs","because","of","problems","in","their","production","at","two","of","the","company","'s","Indian","plants","."],["Then",",","in","February",",","the","FDA","said","Ranbaxy","falsified","data","and","test","results","in","approved","and","pending","drug","applications",",","which","it","said","could","lead","to","defective","products","."],["Daiichi","Sankyo",",","Ranbaxy","'s","Tokyo-based","pharmaceutical","parent",",","has","said","it","is","taking","the","FDA","findings","``","very","seriously","''","and","it","and","Ranbaxy","have","``","formed","a","team","to","solve","this","issue","''","."],["Daiichi","Sankyo","announced","its","4.6-billion-dollar","acquisition","of","a","64-percent","-","stake","in","India","'s","biggest","generic","drugmaker","by","sales","in","June","2008","to","gain","entry","into","the","fast-expanding","global","copycat","drugs","market","."],["But","the","Japanese","firm","has","seen","the","value","of","its","investment","in","Ranbaxy","plummet",",","pushing","it","335.8","billion","yen","-LRB-","3.55","billion","dollars","-RRB-","into","the","red","in","the","last","financial","year","to","March","."]],"part_of_speech":[["NNP","POS","NNP","POS","NN","NN","VBZ","CC","VBZ","NN","NN","."],["JJ","JJ","JJ","NNS","JJ","NNP","NNPS",",","DT","NN","IN","NNP","POS","NNP","NNP",",","VBD","NNP","JJ","NN","VBD","IN","DT","JJ","NN",",","VBN","IN","JJ","NN","NNS","."],["CC","NNP",",","WDT","VBZ","VBN","VBN","IN","JJ","JJ","NNS","IN","PRP$","JJS","NN",",","DT","NNP","NNPS",",","VBD","PRP$","NN","IN","DT","NN","IN","JJ","NN","CD","."],["NNP","POS","JJ","NN","IN","DT","CD","NNS","TO","NNP","VBD","TO","CD","CD","NNS","-LRB-","CD","CD","NNS","-RRB-","IN","CD","CD","NNS","IN","DT","JJ","NN","DT","NN","RBR",",","RB","JJ","NNS","."],["NNS","VBD","VBN","DT","NNP","JJ","NN","TO","VB","CD","JJ","NNS","IN","NNS","IN","DT","JJ","NN","IN","IN","CD","CD","NNS","."],["JJ","NN","NNS",",","NNS","TO","DT","NN","IN","DT","JJ","NN",",","VBD","CD","CD","NNS","."],["CC","VBG","RP","DT","NN","NNS",",","NNP","VBD","DT","JJ","NN","IN","NN","IN","CD","NN","NNS","CC","DT","NN","VBD","PRP","VBD","VBG","TO","DT","JJR","NN","JJ","NN","IN","CD","CD","NNS","IN","DT","NN","."],["``","NNP","NNP","CC","NNP","NNP","-LRB-","NNP","-RRB-","NNS","RB","VBD","NN","NN","IN","DT","NNP",",","''","NNP","VBD","IN","DT","NN","."],["NNS","VBD","TO","CD","CD","NNS","IN","DT","JJ","NN","IN","CD","CD","NNS","DT","NN","RBR",",","VBN","IN","DT","NN","IN","NNP","NNS","."],["``","PRP$","JJ","NN","NN","IN","DT","JJ","NN","IN","VBG","NNS","VBZ","VBN","PRP","VB","DT","NNS",",","''","VBD","NNP","POS","JJ","JJ","NN","NNP","NNP",",","WP","VBD","RP","DT","NN","CD","NNS","RB","."],["DT","NNP","JJ","NNP","VBD","NNS","IN","IN","CD","JJ","NNS","VBN","IN","NNP","VBG","NNS","CC","NN","NNS","IN","IN","NNS","IN","PRP$","NN","IN","CD","IN","DT","NN","POS","JJ","NNS","."],["RB",",","IN","NNP",",","DT","NNP","VBD","NNP","VBD","NNS","CC","NN","NNS","IN","VBN","CC","VBG","NN","NNS",",","WDT","PRP","VBD","MD","VB","TO","JJ","NNS","."],["NNP","NNP",",","NNP","POS","JJ","JJ","NN",",","VBZ","VBD","PRP","VBZ","VBG","DT","NNP","NNS","``","RB","RB","''","CC","PRP","CC","NNP","VBP","``","VBD","DT","NN","TO","VB","DT","NN","''","."],["NNP","NNP","VBD","PRP$","JJ","NN","IN","DT","JJ",":","NN","IN","NNP","POS","JJS","JJ","NN","IN","NNS","IN","NNP","CD","TO","VB","NN","IN","DT","JJ","JJ","JJ","NNS","NN","."],["CC","DT","JJ","NN","VBZ","VBN","DT","NN","IN","PRP$","NN","IN","NNP","VBP",",","VBG","PRP","CD","CD","NNS","-LRB-","CD","CD","NNS","-RRB-","IN","DT","JJ","IN","DT","JJ","JJ","NN","TO","NNP","."]],"totalParse":{"1":[[0,7,"root"],[1,2,"case"],[3,4,"case"],[6,1,"nmod:poss"],[6,3,"nmod:poss"],[6,5,"compound"],[7,6,"nsubj"],[7,8,"cc"],[7,9,"conj$but"],[7,12,"punct"],[9,6,"nsubj"],[9,11,"dobj"],[11,10,"compound"]],"2":[[0,17,"root"],[7,3,"amod"],[7,4,"compound"],[7,5,"amod"],[7,6,"compound"],[7,8,"punct"],[7,10,"appos"],[7,16,"punct"],[7,1,"amod"],[7,2,"amod"],[10,9,"det"],[10,15,"nmod$of"],[12,13,"case"],[15,11,"case"],[15,12,"nmod:poss"],[15,14,"compound"],[17,21,"ccomp"],[17,7,"nsubj"],[17,32,"punct"],[20,19,"amod"],[20,18,"compound"],[21,20,"nsubj"],[21,25,"nmod$during"],[21,26,"punct"],[21,27,"advcl"],[25,22,"case"],[25,23,"det"],[25,24,"amod"],[27,31,"nmod$by"],[31,28,"case"],[31,29,"amod"],[31,30,"compound"]],"3":[[0,21,"root"],[7,6,"auxpass"],[7,11,"nmod$agent"],[7,2,"nsubjpass"],[7,5,"aux"],[11,8,"case"],[11,9,"amod"],[11,10,"amod"],[11,15,"nmod$in"],[15,12,"case"],[15,13,"nmod:poss"],[15,14,"amod"],[19,17,"det"],[19,18,"compound"],[21,23,"dobj"],[21,31,"punct"],[21,1,"cc"],[21,2,"nsubj"],[23,22,"nmod:poss"],[23,26,"nmod$of"],[26,24,"case"],[26,25,"det"],[26,29,"nmod$for"],[29,27,"case"],[29,28,"amod"],[29,30,"nummod"],[2,7,"acl:relcl"],[2,16,"punct"],[2,3,"punct"],[2,19,"appos"],[2,4,"ref"],[2,20,"punct"]],"4":[[0,11,"root"],[1,2,"case"],[4,10,"nmod$to"],[4,1,"nmod:poss"],[4,3,"amod"],[4,8,"nmod$for"],[8,5,"case"],[8,6,"det"],[8,7,"nummod"],[10,9,"case"],[11,15,"nmod$to"],[11,32,"punct"],[11,35,"dobj"],[11,4,"nsubj"],[11,36,"punct"],[11,24,"nmod$from"],[14,13,"compound"],[15,12,"case"],[15,14,"nummod"],[15,19,"dep"],[18,17,"compound"],[19,16,"punct"],[19,18,"nummod"],[19,20,"punct"],[23,22,"compound"],[24,28,"nmod$in"],[24,21,"case"],[24,23,"nummod"],[28,25,"case"],[28,26,"det"],[28,27,"amod"],[28,31,"advmod"],[30,29,"det"],[31,30,"nmod:npmod"],[34,33,"advmod"],[35,34,"amod"]],"5":[[0,3,"root"],[12,14,"nmod$of"],[12,10,"nummod"],[12,11,"amod"],[14,13,"case"],[18,15,"case"],[18,16,"det"],[18,17,"amod"],[18,23,"nmod$of"],[22,20,"advmod"],[22,21,"compound"],[23,19,"case"],[23,22,"nummod"],[3,1,"nsubj"],[3,2,"aux"],[3,7,"dobj"],[3,24,"punct"],[3,9,"xcomp"],[7,4,"det"],[7,5,"compound"],[7,6,"amod"],[9,12,"dobj"],[9,18,"nmod$with"],[9,7,"nsubj"],[9,8,"mark"]],"6":[[0,3,"root"],[16,15,"compound"],[17,16,"nummod"],[3,1,"amod"],[3,2,"compound"],[3,18,"punct"],[3,4,"punct"],[3,5,"appos"],[3,13,"punct"],[3,14,"acl"],[5,8,"nmod$to"],[8,6,"case"],[8,7,"det"],[8,12,"nmod$in"],[12,9,"case"],[12,10,"det"],[12,11,"amod"],[14,17,"dobj"]],"7":[[0,9,"root"],[18,15,"case"],[18,16,"nummod"],[18,17,"compound"],[21,20,"det"],[22,25,"ccomp"],[22,12,"nsubj"],[25,23,"nsubj"],[25,24,"aux"],[25,31,"nmod$to"],[31,35,"nmod$of"],[31,38,"nmod$for"],[31,26,"case"],[31,27,"det"],[31,28,"amod"],[31,29,"amod"],[31,30,"amod"],[34,33,"compound"],[35,34,"nummod"],[35,32,"case"],[38,36,"case"],[38,37,"det"],[2,3,"compound:prt"],[2,6,"dobj"],[6,4,"det"],[6,5,"compound"],[9,2,"advcl"],[9,22,"ccomp"],[9,7,"punct"],[9,39,"punct"],[9,8,"nsubj"],[9,1,"cc"],[12,21,"nmod$after"],[12,10,"det"],[12,11,"amod"],[12,14,"nmod$after"],[14,18,"nmod$of"],[14,19,"cc"],[14,21,"conj$and"],[14,13,"case"]],"8":[[0,21,"root"],[3,6,"conj$and"],[3,2,"compound"],[3,4,"cc"],[6,5,"compound"],[6,8,"appos"],[8,7,"punct"],[8,9,"punct"],[10,6,"compound"],[10,3,"compound"],[12,10,"nsubj"],[12,11,"advmod"],[12,14,"dobj"],[14,13,"compound"],[14,17,"nmod$in"],[17,15,"case"],[17,16,"det"],[21,24,"nmod$in"],[21,25,"punct"],[21,12,"ccomp"],[21,1,"punct"],[21,18,"punct"],[21,19,"punct"],[21,20,"nsubj"],[24,22,"case"],[24,23,"det"]],"9":[[0,2,"root"],[25,24,"compound"],[25,23,"case"],[2,10,"nmod$during"],[2,26,"punct"],[2,14,"nmod$from"],[2,1,"nsubj"],[2,18,"punct"],[2,19,"xcomp"],[2,6,"nmod$to"],[5,4,"compound"],[6,3,"case"],[6,5,"nummod"],[10,8,"det"],[10,9,"amod"],[10,7,"case"],[13,12,"compound"],[14,11,"case"],[14,13,"nummod"],[14,17,"advmod"],[16,15,"det"],[17,16,"nmod:npmod"],[19,22,"nmod$by"],[22,25,"nmod$in"],[22,20,"case"],[22,21,"det"]],"10":[[0,21,"root"],[5,2,"nmod:poss"],[5,3,"amod"],[5,4,"compound"],[5,9,"nmod$with"],[9,12,"nmod$on"],[9,6,"case"],[9,7,"det"],[9,8,"amod"],[12,11,"amod"],[12,10,"case"],[14,13,"aux"],[14,16,"ccomp"],[14,1,"punct"],[14,5,"nsubj"],[16,15,"nsubj"],[16,18,"dobj"],[18,17,"det"],[21,28,"nsubj"],[21,14,"ccomp"],[21,19,"punct"],[21,20,"punct"],[21,38,"punct"],[22,23,"case"],[28,27,"compound"],[28,29,"punct"],[28,30,"ref"],[28,31,"acl:relcl"],[28,22,"nmod:poss"],[28,24,"amod"],[28,25,"amod"],[28,26,"compound"],[31,28,"nsubj"],[31,32,"compound:prt"],[31,34,"dobj"],[31,37,"advmod"],[34,33,"det"],[36,35,"nummod"],[37,36,"nmod:npmod"]],"11":[[0,5,"root"],[30,31,"case"],[30,29,"det"],[33,30,"nmod:poss"],[33,32,"amod"],[33,28,"case"],[2,1,"det"],[4,3,"amod"],[5,2,"nsubj"],[5,34,"punct"],[5,4,"nmod:tmod"],[5,6,"dobj"],[6,11,"nmod$over"],[6,12,"acl"],[11,7,"case"],[11,8,"case"],[11,9,"nummod"],[11,10,"amod"],[12,14,"nmod$by"],[12,22,"nmod$because_of"],[14,16,"nmod$including"],[14,19,"nmod$including"],[14,13,"case"],[16,15,"case"],[16,17,"cc"],[16,19,"conj$and"],[19,18,"compound"],[20,21,"mwe"],[22,20,"case"],[22,25,"nmod$in"],[22,27,"nmod$at"],[25,23,"case"],[25,24,"nmod:poss"],[27,33,"nmod$of"],[27,26,"case"]],"12":[[0,8,"root"],[4,3,"case"],[7,6,"det"],[8,1,"advmod"],[8,2,"punct"],[8,4,"nmod$in"],[8,5,"punct"],[8,7,"nsubj"],[8,10,"ccomp"],[8,30,"punct"],[10,9,"nsubj"],[10,14,"dobj"],[10,14,"dobj"],[11,12,"cc"],[11,13,"conj$and"],[14,17,"cc"],[14,11,"compound"],[14,13,"compound"],[14,14,"conj$and"],[14,16,"acl$in"],[14,20,"acl$pending"],[16,21,"punct"],[16,24,"ccomp"],[16,15,"case"],[20,18,"case"],[20,19,"compound"],[24,22,"dobj"],[24,23,"nsubj"],[24,26,"ccomp"],[26,25,"aux"],[26,29,"nmod$to"],[29,27,"case"],[29,28,"amod"]],"13":[[0,11,"root"],[2,8,"appos"],[2,9,"punct"],[2,1,"compound"],[2,3,"punct"],[4,5,"case"],[8,4,"nmod:poss"],[8,6,"amod"],[8,7,"amod"],[11,36,"punct"],[11,10,"aux"],[11,28,"ccomp"],[11,14,"ccomp"],[11,2,"nsubj"],[14,20,"advmod"],[14,21,"punct"],[14,22,"cc"],[14,12,"nsubj"],[14,28,"conj$and"],[14,13,"aux"],[14,17,"dobj"],[14,18,"punct"],[17,15,"det"],[17,16,"compound"],[20,19,"advmod"],[23,24,"cc"],[23,25,"conj$and"],[28,23,"nsubj"],[28,25,"nsubj"],[28,26,"aux"],[28,27,"punct"],[28,30,"dobj"],[28,32,"advcl"],[30,29,"det"],[32,31,"mark"],[32,34,"dobj"],[32,35,"punct"],[34,33,"det"]],"14":[[0,3,"root"],[9,10,"punct"],[11,7,"case"],[11,8,"det"],[11,9,"amod"],[11,17,"nmod$in"],[13,14,"case"],[17,12,"case"],[17,13,"nmod:poss"],[17,15,"amod"],[17,16,"amod"],[19,18,"case"],[19,21,"nmod$in"],[21,20,"case"],[21,22,"nummod"],[24,23,"mark"],[24,25,"dobj"],[25,32,"nmod$into"],[32,26,"case"],[32,27,"det"],[32,28,"amod"],[32,29,"amod"],[32,30,"amod"],[32,31,"compound"],[2,1,"compound"],[3,24,"advcl"],[3,33,"punct"],[3,2,"nsubj"],[3,19,"nmod$by"],[3,6,"dobj"],[6,11,"nmod$of"],[6,4,"nmod:poss"],[6,5,"amod"]],"15":[[0,6,"root"],[4,2,"det"],[4,3,"amod"],[6,14,"ccomp"],[6,1,"cc"],[6,4,"nsubj"],[6,36,"punct"],[6,5,"aux"],[8,11,"nmod$of"],[8,13,"nmod$in"],[8,7,"det"],[11,10,"nmod:poss"],[11,9,"case"],[13,12,"case"],[14,15,"punct"],[14,16,"xcomp"],[14,8,"nsubj"],[16,17,"dobj"],[17,20,"dep"],[19,18,"compound"],[20,28,"nmod$into"],[20,33,"nmod$in"],[20,19,"nummod"],[20,35,"nmod$to"],[20,24,"appos"],[23,22,"compound"],[24,21,"punct"],[24,23,"nummod"],[24,25,"punct"],[28,26,"case"],[28,27,"det"],[33,29,"case"],[33,30,"det"],[33,31,"amod"],[33,32,"amod"],[35,34,"case"]]},"processed":{"1":[{"edgeName":"nsubj","govWord":"soars but sees .","depWord":"India Ranbaxy Q2 profit","dep":[1,3,5,6],"gov":[7,8,9,12]},{"edgeName":"nsubj","govWord":"sees loss","depWord":"India Ranbaxy Q2 profit","dep":[1,3,5,6],"gov":[9,11]},{"edgeName":"dobj","govWord":"profit sees","depWord":"year loss","dep":[10,11],"gov":[6,9]}],"2":[{"edgeName":"appos","govWord":"Top Indian generic drugs firm Ranbaxy Laboratories , ,","depWord":"a unit Sankyo","dep":[9,10,15],"gov":[1,2,3,4,5,6,7,8,16]},{"edgeName":"nsubj","govWord":"reported soared .","depWord":"Top Indian generic drugs firm Ranbaxy Laboratories , unit ,","dep":[1,2,3,4,5,6,7,8,10,16],"gov":[17,21,32]},{"edgeName":"nsubj","govWord":"soared quarter , swelled","depWord":"Friday net profit","dep":[18,19,20],"gov":[21,25,26,27]}],"3":[{"edgeName":"nsubjpass","govWord":"has been buffeted problems","depWord":"Ranbaxy , which , States ,","dep":[2,3,4,16,19,20],"gov":[5,6,7,11]},{"edgeName":"dobj","govWord":"But Ranbaxy maintained .","depWord":"its forecast loss","dep":[22,23,26],"gov":[1,2,21,31]},{"edgeName":"nsubj","govWord":"But maintained forecast .","depWord":"Ranbaxy , which buffeted , States ,","dep":[2,3,4,7,16,19,20],"gov":[1,21,23,31]},{"edgeName":"appos","govWord":"Ranbaxy , which buffeted , ,","depWord":"the United States","dep":[17,18,19],"gov":[2,3,4,7,16,20]}],"4":[{"edgeName":"dobj","govWord":"profit jumped rupees rupees , .","depWord":"surprising analysts","dep":[34,35],"gov":[4,11,15,24,32,36]},{"edgeName":"nsubj","govWord":"jumped rupees rupees , analysts .","depWord":"Ranbaxy net profit months June","dep":[1,3,4,8,10],"gov":[11,15,24,32,35,36]}],"5":[{"edgeName":"nsubj","govWord":"had expected company snap .","depWord":"Analysts","dep":[1],"gov":[2,3,7,9,24]},{"edgeName":"dobj","govWord":"Analysts had expected snap .","depWord":"the New Delhi-based company","dep":[4,5,6,7],"gov":[1,2,3,9,24]},{"edgeName":"dobj","govWord":"company to snap profit","depWord":"three straight quarters losses","dep":[10,11,12,14],"gov":[7,8,9,18]},{"edgeName":"nsubj","govWord":"to snap quarters profit","depWord":"the New Delhi-based company","dep":[4,5,6,7],"gov":[8,9,12,18]}],"6":[{"edgeName":"appos","govWord":"Foreign exchange gains , , totalled .","depWord":"thanks rise","dep":[5,8],"gov":[1,2,3,4,13,14,18]},{"edgeName":"dobj","govWord":"totalled","depWord":"billion rupees","dep":[16,17],"gov":[14]}],"7":[{"edgeName":"nsubj","govWord":"said sticking","depWord":"a second-quarter profit tax company","dep":[10,11,12,14,21],"gov":[22,25]},{"edgeName":"nsubj","govWord":"was sticking loss","depWord":"it","dep":[23],"gov":[24,25,31]},{"edgeName":"dobj","govWord":"stripping out","depWord":"the currency gains","dep":[4,5,6],"gov":[2,3]},{"edgeName":"nsubj","govWord":"But stripping , posted said .","depWord":"Ranbaxy","dep":[8],"gov":[1,2,7,9,22,39]}],"8":[{"edgeName":"appos","govWord":"Drug Administration","depWord":"-LRB- FDA -RRB-","dep":[7,8,9],"gov":[5,6]},{"edgeName":"nsubj","govWord":"adversely impacted performance","depWord":"Food Administration actions","dep":[3,6,10],"gov":[11,12,14]},{"edgeName":"dobj","govWord":"actions adversely impacted","depWord":"business performance USA","dep":[13,14,17],"gov":[10,11,12]},{"edgeName":"nsubj","govWord":"`` impacted , '' said statement .","depWord":"Ranbaxy","dep":[20],"gov":[1,12,18,19,21,24,25]}],"9":[{"edgeName":"nsubj","govWord":"fell rupees period rupees , hit .","depWord":"Sales","dep":[1],"gov":[2,6,10,14,18,19,26]}],"10":[{"edgeName":"nsubj","govWord":"`` has helped mitigate","depWord":"Our balanced market mix focus","dep":[2,3,4,5,9],"gov":[1,13,14,16]},{"edgeName":"nsubj","govWord":"mitigate pressures","depWord":"us","dep":[15],"gov":[16,18]},{"edgeName":"dobj","govWord":"us mitigate","depWord":"these pressures","dep":[17,18],"gov":[15,16]},{"edgeName":"nsubj","govWord":"helped , '' said .","depWord":"Ranbaxy new chief executive Atul Sobti , who took","dep":[22,24,25,26,27,28,29,30,31],"gov":[14,19,20,21,38]},{"edgeName":"nsubj","govWord":"took over job ago","depWord":"Ranbaxy new chief executive Atul Sobti , who","dep":[22,24,25,26,27,28,29,30],"gov":[31,32,34,37]},{"edgeName":"dobj","govWord":"Sobti took over ago","depWord":"the job","dep":[33,34],"gov":[28,31,32,37]}],"11":[{"edgeName":"nsubj","govWord":"September banned imports .","depWord":"The FDA","dep":[1,2],"gov":[4,5,6,34]},{"edgeName":"dobj","govWord":"FDA September banned .","depWord":"imports drugs produced","dep":[6,11,12],"gov":[2,4,5,34]}],"12":[{"edgeName":"nsubj","govWord":"Then , February , said falsified .","depWord":"the FDA","dep":[6,7],"gov":[1,2,4,5,8,10,30]},{"edgeName":"nsubj","govWord":"falsified results results","depWord":"Ranbaxy","dep":[9],"gov":[10,14,14]},{"edgeName":"dobj","govWord":"Ranbaxy falsified results","depWord":"data test results results approved and","dep":[11,13,14,14,16,17],"gov":[9,10,14]},{"edgeName":"dobj","govWord":"Ranbaxy falsified results","depWord":"results applications","dep":[14,20],"gov":[9,10,14]},{"edgeName":"dobj","govWord":"it said lead","depWord":"which","dep":[22],"gov":[23,24,26]},{"edgeName":"nsubj","govWord":"which said lead","depWord":"it","dep":[23],"gov":[22,24,26]}],"13":[{"edgeName":"appos","govWord":"Daiichi Sankyo , ,","depWord":"Ranbaxy Tokyo-based pharmaceutical parent","dep":[4,6,7,8],"gov":[1,2,3,9]},{"edgeName":"nsubj","govWord":"has said taking formed .","depWord":"Daiichi Sankyo , parent ,","dep":[1,2,3,8,9],"gov":[10,11,14,28,36]},{"edgeName":"nsubj","govWord":"is taking findings `` seriously '' and formed","depWord":"it","dep":[12],"gov":[13,14,17,18,20,21,22,28]},{"edgeName":"dobj","govWord":"it is taking `` seriously '' and formed","depWord":"the FDA findings","dep":[15,16,17],"gov":[12,13,14,18,20,21,22,28]},{"edgeName":"nsubj","govWord":"Ranbaxy have `` formed team solve","depWord":"it and Ranbaxy","dep":[23,24,25],"gov":[25,26,27,28,30,32]},{"edgeName":"nsubj","govWord":"it have `` formed team solve","depWord":"Ranbaxy","dep":[25],"gov":[23,26,27,28,30,32]},{"edgeName":"dobj","govWord":"it Ranbaxy have `` formed solve","depWord":"a team","dep":[29,30],"gov":[23,25,26,27,28,32]},{"edgeName":"dobj","govWord":"to solve ''","depWord":"this issue","dep":[33,34],"gov":[31,32,35]}],"14":[{"edgeName":"dobj","govWord":"to gain","depWord":"entry market","dep":[25,32],"gov":[23,24]},{"edgeName":"nsubj","govWord":"announced acquisition sales gain .","depWord":"Daiichi Sankyo","dep":[1,2],"gov":[3,6,19,24,33]},{"edgeName":"dobj","govWord":"Sankyo announced sales gain .","depWord":"its 4.6-billion-dollar acquisition stake","dep":[4,5,6,11],"gov":[2,3,19,24,33]}],"15":[{"edgeName":"nsubj","govWord":"But has seen plummet .","depWord":"the Japanese firm","dep":[2,3,4],"gov":[1,5,6,14,36]},{"edgeName":"nsubj","govWord":"plummet , pushing","depWord":"the value investment Ranbaxy","dep":[7,8,11,13],"gov":[14,15,16]},{"edgeName":"dobj","govWord":"pushing","depWord":"it yen","dep":[17,20],"gov":[16]},{"edgeName":"appos","govWord":"billion yen red year March","depWord":"-LRB- billion dollars -RRB-","dep":[21,23,24,25],"gov":[19,20,28,33,35]}]}}